1. Inicio
  2. Publicaciones
  3. Eculizumab in secondary atypical haemolytic uraemic syndrome

Eculizumab in secondary atypical haemolytic uraemic syndrome

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Cavero, T
  • Rabasco, C
  • Lopez, A
  • Avila, A
  • Sevillano, A
  • Huerta, A
  • Rojas-Rivera, J
  • Blasco, M
  • Jarque, A
  • Garcia, A
  • Mendizabal, S
  • Gavela, E
  • Macia, M
  • Quintana, LF
  • María Romera A
  • Borrego, J
  • Arjona, E
  • Espinosa, M
  • Portoles, J
  • Gracia-Iguacel, C
  • Gonzalez-Parra, E
  • Aljama, P
  • Morales, E
  • Cao, M
  • Rodríguez de Córdoba S
  • Praga, M

Grupos

Abstract

Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab. Methods. We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Primary outcome was TMA resolution, defined by a normalization of platelet count (> 150 x 10(9)/L) and haemoglobin, disappearance of all the markers of microangiopathic haemolytic anaemia (MAHA), and improvement of renal function, with a >= 25% reduction of serum creatinine from the onset of eculizumab administration. Results. Twenty-nine patients with secondary aHUS (15 druginduced, 8 associated with systemic diseases, 2 with postpartum, 2 with cancer-related, 1 associated with acute humoral rejection and 1 with intestinal lymphangiectasia) were included in this study. The reason to initiate eculizumab treatment was worsening of renal function and persistence of TMA despite treatment of the TMA cause and plasmapheresis. All patients showed severe MAHA and renal function impairment (14 requiring dialysis) prior to eculizumab treatment and 11 presented severe extrarenal manifestations. A rapid resolution of the TMA was observed in 20 patients (68%), 15 of them showing a >= 50% serum creatinine reduction at the last follow-up. Comprehensive genetic and molecular studies in 22 patients identified complement pathogenic variants in only 2 patients. With these two exceptions, eculizumab was discontinued, after a median of 8 weeks of treatment, without the occurrence of aHUS relapses. Conclusion. Short treatment with eculizumab can result in a rapid improvement of patients with secondary aHUS in whom TMA has persisted and renal function worsened despite treatment of the TMA-inducing condition.

Datos de la publicación

ISSN/ISSNe:
0931-0509, 1460-2385

NEPHROLOGY DIALYSIS TRANSPLANTATION  OXFORD UNIV PRESS

Tipo:
Article
Páginas:
466-474
Factor de Impacto:
2,142 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 89

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • atypical haemolytic uraemic syndrome; complement activation; eculizumab; thrombotic microangiopathies

Proyectos asociados

DIAGNÓSTICO GENÉTICO MOLECULAR DE LAS CILIOPATÍAS RENALES MEDIANTE SECUENCIACIÓN MASIVA DE NUEVA GENERACIÓN (NGS).

Investigador Principal: MARIA JOSE APARISI NAVARRO

GV/2016/057 . 2016

REGISTRO NACIONAL DE RECHAZO HUMORAL: ESTUDIO EPIDEMIOLOGICO MULTICENTRICO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LAS CARACTERISTICAS CLINICAS, SEROLOGICAS E HISTOLOGICAS Y LA EVOLUCION A 5 AÑOS DEL RECHAZO HUMORAL POST-TRASPLANTE RENAL EN ESPAÑA

Investigador Principal: ISABEL BENEYTO CASTELLO

HUMORAL-KTX . 2011

UN ESTUDIO OBSERVACIONAL, NO INTERVENCIONISTA, MULTICÉNTRICO Y MULTINACIONAL DE PACIENTES CON SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO (REGISTRO DE SHUA).

Investigador Principal: ELENA ROMÁN ORTIZ

ALE-ECU-2012-01 . 2013

SIOP EPENDIMOMA - PROGRAMA CLÍNICO INTERNACIONAL PARA EL DIAGNÓSTICO Y TRATAMIENTO DE NIÑOS, ADOLESCENTES Y ADULTOS JÓVENES CON EPENDIMOMA.

Investigador Principal: ADELA CAÑETE NIETO

ET13-002 . 2019

ESTUDIO EN FASE I/II DE BÚSQUEDA DE DOSIS DE CH14.18/CHO EN INFUSIÓN CONTINUA COMBINADO CON ALDESLEUKINA (IL-2) SUBCUTÁNEA EN PACIENTES CON NEUROBLASTOMA PRIMARIO REFRACTARIO O EN RECAÍDA.

Investigador Principal: VICTORIA CASTEL SÁNCHEZ

012010 . 2012

PROTOCOLO EUROPEO DE TRATAMIENTO PARA EL NEUROBLASTOMA DE RIESGO BAJO O INTERMEDIO.

Investigador Principal: ADELA CAÑETE NIETO

LINES . 2011

ESTUDIO DE FASE I-II SOBRE LA SEGURIDAD Y LA EFICACIA DE DACOGEN EN ADMINISTRACIÓN SECUENCIAL CON CITARABINA EN NIÑOS CON LEUCEMIA MIELOIDE AGUDA RECIDIVANTE O RESISTENTE AL TRATAMIENTO.

Investigador Principal: JOSÉ MARÍA FERNÁNDEZ NAVARRO

DACOGENAML2004 . 2015

ESTUDIO FASE I-II DE VINBLASTINA EN COMBINACIÓN CON NILOTINIB EN NIÑOS, ADOLESCENTES, Y ADULTOS JÓVENES CON GLIOMA DE BAJO GRADO REFRACTARIO O RECURRENTE.

Investigador Principal: ADELA CAÑETE NIETO

IGR2012/1883 . 2015

SEGUNDO ESTUDIO INTERNACIONAL INTERGRUPO PARA EL LINFOMA DE HODGKIN CLÁSICO EN NIÑOS Y ADOLESCENTES.

Investigador Principal: MARÍA DEL MAR ANDRÉS MORENO

EURONET-PHL-C2 . 2016

Cita

Compartir